Concepedia

Belinda Cancilla

BC

22

Publications

3.6K

Citations

20

H-Index

1996

Active since

Affiliations

Monash University(Current)

Exelixis (United States)

OncoMed (United States)

The University of Melbourne

Monash Institute of Medical Research

Belinda Cancilla is an author at Monash University specializing in medicine, cell biology, and tumor biology.

Top concepts

Publications per year

1996–2017

22

Publications

22

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

, , +13

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer

Jing Shan Lim, Alvaro Ibaseta, Marcus Fischer et al. · Nature · 2017 · 482 citations · Full text

, , +5

Development of the Zebrafish Lymphatic System Requires Vegfc Signaling

Axel M. Küchler, Evisa Gjini, Josi Peterson-Maduro et al. · Current Biology · 2006 · 283 citations · Full text

, , +3

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

Wan-Ching Yen, Marcus Fischer, Fumiko Axelrod et al. · Clinical Cancer Research · 2015 · 239 citations

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman et al. · Clinical Cancer Research · 2010 · 191 citations · Full text

Rows per page

1–5 of 22